Read by QxMD icon Read

Relapsed b-cell lymphoma

Greg P Coffey, Greg P Coffey, Andreas Betz, Jiajia Feng, Anjali Pandey, Matt Birrell, Janet M Leeds, Kenneth Der, Sabah Kadri, Pin Lu, Jeremy P Segal, Y Lynn Wang, Glenn Michelson, John T Curnutte, Pamela B Conley
PURPOSE: Preclinical studies suggest SYK and JAK contribute to tumor intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated. EXPERIMENTAL DESIGN: In a phase I dose-escalation study in adults with relapsed/refractory B-cell malignancies, cerdulatinib was administered orally to sequential dose-escalation cohorts using once-daily or twice-daily schedules...
October 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Hanno M Witte, Armin Riecke, Thomas Mayer, Tobias Bartscht, Dirk Rades, Hendrik Lehnert, Hartmut Merz, Sebastian Fetscher, Harald Biersack, Niklas Gebauer
PURPOSE: The introduction of immunochemotherapy has led to a significant improvement in treatment results and prognosis of diffuse large B-cell non-Hodgkins lymphoma (DLBCL) both at initial diagnosis and in relapse. Trofosfamide, an oxazaphosphorine derivative, has been utilized as alternative treatment option for patients with lymphoproliferative diseases unsuitable for conventional chemotherapy agents and protocols because of age, comorbidity, or poor performance score. While data on the activity and safety of single-agent trofosfamide have been published, the potential value of this agent in immunochemotherapy in combination with anti-CD20 antibodies such as rituximab has not been investigated to our knowledge...
October 16, 2018: Journal of Cancer Research and Clinical Oncology
Adriano Pellicelli, Valerio Giannelli, Valerio Zoli, Valeria Pellicelli, Anna Linda Zignego
Introduction: Hepatitis C infection (HCV) is highly prevalent worldwide and has a well-known association with B-cell lymphoid malignancies. While several studies have demonstrated that antiviral therapy (AT) is effective to induce a complete hematological response in HCV-related low-grade B cell lymphoma, in HCV-related high-grade B cell non-Hodgkin lymphomas such as diffuse large B cell lymphoma (DLBCL) chemotherapy is the only possible choice. However, the role of AT to reduce relapse of DLBCL after an effective chemotherapy containing rituximab (CT-R) has not been analyzed in previous studies...
September 2018: Clinical and Experimental Hepatology
Mireia Franch-Sarto, Marc Sorigue, Laia López, Miriam Moreno, Josep-Maria Ribera, Juan-Manuel Sancho
No abstract text is available yet for this article.
October 15, 2018: Leukemia & Lymphoma
S W G J W Chinthaka, R L Satarasinghe, S Senanayake, W A P S R Weerarathne, A A M Anfaz, M P Deraniyagala
BACKGROUND: Lymphadenopathy is not an uncommon presentation of adult onset Still's disease: it is present in up to two thirds of patients with adult onset Still's disease. The characteristic appearance of lymphadenopathy is described as intense, paracortical immunoblastic hyperplasia. Changes in light microscopy may resemble lymphoma, but immunohistochemistry reveals a benign polyclonal B cell hyperplasia. CASE PRESENTATION: We describe a 67-year-old Sri Lankan woman who manifested relapsing prolonged fever, raised inflammatory markers, arthralgia, myalgia, transient skin rash, and cervical lymphadenopathy histologically characterized by noncaseating granulomatous adenitis with central suppuration...
October 15, 2018: Journal of Medical Case Reports
Carlos A Ramos, Rayne Rouce, Catherine S Robertson, Amy Reyna, Neeharika Narala, Gayatri Vyas, Birju Mehta, Huimin Zhang, Olga Dakhova, George Carrum, Rammurti T Kamble, Adrian P Gee, Zhuyong Mei, Meng-Fen Wu, Hao Liu, Bambi Grilley, Cliona M Rooney, Helen E Heslop, Malcolm K Brenner, Barbara Savoldo, Gianpietro Dotti
Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduced T cell products (CD19...
September 13, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
Anahita Nosrati, Ahmad Monabati, Alireza Sadeghipour, Fatemeh Radmanesh, Akbar Safaei, Sajjadeh Movahedinia
Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL...
October 11, 2018: Annals of Hematology
Sarah Löw, Catherine H Han, Tracy T Batchelor
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal non-Hodgkin lymphoma (NHL), confined to the brain, eyes, spinal cord or leptomeninges without systemic involvement. Overall prognosis, diagnosis and management of PCNSL differ from other types of NHL. Prompt diagnosis and initiation of treatment are vital to improving clinical outcomes. PCNSL is responsive to radiation therapy, however whole-brain radiotherapy (WBRT) inadequately controls the disease when used alone and its delayed neurotoxicity causes neurocognitive impairment, especially in elderly patients...
2018: Therapeutic Advances in Neurological Disorders
Kiyoshi Ando
Follicular lymphoma (FL) is a neoplasm comprising germinal center B cells, which typically has, at least, a partially follicular pattern. Although the natural course of the disease is indolent, the chemosensitivity is low, which results in frequent relapse and immunosuppression. Therefore, the tumor stage and tumor burden are essential criteria for deciding on the treatment strategy. For advanced-stage patients with a low tumor burden, watchful waiting is a standard option. The optimal timing for administrating rituximab is a critical clinical question...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Shaoxuan Hu, Yuqin Song, Xiuhua Sun, Liping Su, Wei Zhang, Jing Jia, Ou Bai, Sheng Yang, Rong Liang, Xiaoling Li, Huilai Zhang, Yuhuan Gao, Weijing Zhang, Xiubin Xiao, Huizheng Bao, Ningju Wang, Hanyun Ren, Xinan Cen, Shun'e Yang, Yu Zhao, Yinan Wang, Yalan Wang, Aichun Liu, Jingwen Wang, Yuankai Shi, Ming Yuan, Yufu Li, Xiaohui He
Primary breast diffuse large B-cell lymphoma(PB-DLBCL) is a rare subtype of DLBCL with limited data on patterns of failure. This multicenter study aimed to define the optimum treatment strategy and patterns of failure for PB-DLBCL patients. We retrospectively reviewed data on 108 PB-DLBCL patients from 21 Chinese medical centers. Only patients with localized disease (involvement of breast and localized lymph nodes) were included. After a median follow-up of 3.2 years, 32% of patients developed progression or relapse...
October 9, 2018: Cancer Science
Tony Reiman, Kerry J Savage, Michael Crump, Matthew C Cheung, David MacDonald, Rena Buckstein, Stephen Couban, Eugenia Piliotis, Kevin Imrie, David Spaner, Sudeep Shivakumar, John Kuruvilla, Diego Villa, Lois E Shepherd, Tanya Skamene, Chad Winch, Bingshu E Chen, Annette E Hay
We investigated GDP (gemcitabine, 1000 mg/m2 IV d1, d8; dexamethasone, 40 mg po d1-4; cisplatin, 75 mg/m2 IV d1) combined with romidepsin on days 1 and 8 every 21 days to a maximum of six cycles in a standard 3 + 3, phase I dose escalation trial for patients with relapsed/refractory peripheral T-cell (PTCL) or diffuse large B-cell (DLBCL) lymphoma (NCT01846390). After treating four patients, gemcitabine and romidepsin were given on days 1 and 15 every 28 days. On the 21-day schedule at 6 mg/m2 romidepsin, there were three dose-limiting toxicities (DLTs) among four patients...
October 10, 2018: Leukemia & Lymphoma
Meng-Tian Jiang, Jian-Ping Yin, Yi-Cheng Zhang, Wei Ma, Ru Yang
OBJECTIVE: To analyze the effect of autologous hematopoietic stem cell transplantation in the treatment of patients with recurrent refractory B cell non-Hodgkin's lymphoma (NHL) and the related factors affecting the prognosis. METHODS: The clinical data of 47 cases of recurrent refractory B cell NHL treated in our hospital were retrospectively analyzed. Survival curves were drawn by Kaplan-Meier, and survival analyses were performed. Univariate and multivariate analyses were used to analyze the prognostic factors...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Ping Yang, Yuan-Yuan Liu, Ran An, Jing-Fei Zhen, Meng Pang, Wei Zhao, Kai Hu, Wei Wan, Xiao-Yan Ke, Hong-Mei Jing
OBJECTIVE: To analyse the clinical characteristics and therapeutic efticacy of patients with mantle cell lymphoma(MCL). METHODS: The clinical data including cliniced parameters and laboratorial test results of 54 patients with MCL were collected and restrospectively analyzed to clarity the clinical characteristics of MCL and to evaluate the survival and factors affecting prgnosis of patients. RESULTS: The incidence of MCL accounted for 4.0% of NHL in our center...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A Portell, Alan P Skarbnik, Amanda F Cashen, David T Weaver, Virginia M Kelly, Barry Turnbull, Stephan Stilgenbauer
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphoinositide 3-kinase (PI3K) δ and -γ being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling can promote B cell proliferation and survival in clonal B cell malignancies, such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a Phase 1 study, duvelisib showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here the results of DUO™, a global Phase 3 randomized study of duvelisib versus ofatumumab monotherapy for patients with relapsed or refractory (RR) CLL/SLL...
October 4, 2018: Blood
Wojciech Jurczak, Monika Długosz-Danecka, Fernando Rivas Navarro
Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells...
October 3, 2018: Future Oncology
Monika A Jakubowska, Martijn Kerkhofs, Claudio Martines, Dimitar G Efremov, Julia V Gerasimenko, Oleg V Gerasimenko, Ole H Petersen, Geert Bultynck, Tim Vervliet, Pawel E Ferdek
BACKGROUND AND PURPOSE: Many cancer cells depend on anti-apoptotic B cell lymphoma 2 (Bcl-2) proteins for their survival. Bcl-2 antagonism through BH3 mimetics emerged as novel anti-cancer therapy. ABT-199 (Venetoclax), a recently developed BH3 mimetic inhibiting selectively Bcl-2, was introduced into the clinic for treatment of relapsed chronic lymphocytic leukaemia. Early generations of Bcl-2 inhibitors evoked sustained Ca2+ responses in pancreatic acinar cells (PACs) inducing cell death...
September 28, 2018: British Journal of Pharmacology
Lauren P McLaughlin, Rayne Rouce, Stephen Gottschalk, Vicky Torrano, George Carrum, Meng-Fen Wu, Fahmida Hoq, Bambi Grilley, Andrea M Marcogliese, Patrick J Hanley, Adrian P Gee, Malcolm K Brenner, Cliona M Rooney, Helen E Heslop, Catherine M Bollard
Autologous T cells targeting Epstein Barr virus (EBV) latent membrane proteins (LMPs) have shown safety and efficacy for the treatment of patients with type II latency EBV-associated lymphomas who have failed standard therapies, including high dose chemotherapy followed by autologous stem cell rescue. However, the safety and efficacy of allogeneic donor-derived LMP-specific T cells (LMP-Ts) have not been established for patients who have received allogeneic HSCT. Thus, we evaluated the safety and efficacy of donor-derived LMP-Ts in 26 patients who had received an allogeneic hematopoietic stem cell transplant (HSCT) for EBV-associated T/NK or B cell lymphomas (NCT00062868, NCT01956084; ClinicalTrials...
September 27, 2018: Blood
Joshua A Roth, Sean D Sullivan, Vincent W Lin, Aasthaa Bansal, Anna G Purdum, Lynn Navale, Paul Cheng, Scott D Ramsey
PURPOSE: Axicabtagene ciloleucel (axi-cel) was recently approved for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL) following two or more prior therapies. As the first CAR T-cell therapy available for adults in the US, there are important questions about clinical and economic value. The objective of this study was to assess the cost-effectiveness of axi-cel compared to salvage chemotherapy using a decision model and a US payer perspective. MATERIALS AND METHODS: A decision model was developed to estimate life years (LYs), quality-adjusted life years (QALYs), and lifetime cost for adult patients with R/R LBCL treated with axi-cel vs salvage chemotherapy (R-DHAP)...
October 16, 2018: Journal of Medical Economics
Sudjit Luanpitpong, Jirarat Poohadsuan, Parinya Samart, Chayanin Kiratipaiboon, Yon Rojanasakul, Surapol Issaragrisil
Mantle cell lymphoma (MCL) is an aggressive, incurable non-Hodgkin B-cell lymphoma with good initial response to therapy then subsequently relapse. Cancer stem cells (CSCs) are considered to be an underlying cause of these inevitable drug resistance and tumor regrowth, but how CSCs are regulated is largely unknown. We demonstrate here for the first time the existence of CSC-like subpopulations that are modulated by reactive oxygen species (ROS) in MCL cell lines and patient-derived primary cells in an inverse correlation with bortezomib (BTZ) sensitivity...
November 2018: Biochimica et biophysica acta. Molecular basis of disease
Bin Luo, Yong-Yao Gu, Xiao-Dong Wang, Gang Chen, Zhi-Gang Peng
Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs were analyzed using the Database for Annotation, Visualization, and Integrated Discovery...
September 16, 2018: Pathology, Research and Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"